ACTU Stock Forecast & Price Target

Actuate Therapeutics is a promising company with a strong potential for growth in the biopharmaceutical industry. With a diverse pipeline and promising data from clinical trials, the company has a strong chance of success in their development of elraglusib for the treatment of high impact cancers. The company's financials also show strong potential, with a projected net present value of $644.3M and net cash of $8.1M expected in the next 12 months, demonstrating their sound financial management. Possible risks include financial, clinical, manufacturing, and regulatory factors, but overall the company has a positive risk-benefit balance with a high likelihood of success.

Actuate Therapeutics is facing potential financial challenges and risks, as they are relying on their current data package for potential conditional marketing authorization in the EU while also facing a need for further confirmatory studies for elraglusib. With a projected future revenue of $656M and net cash of $13.1M, their 12-month price target of $15 is significantly lower than their previous price target of $20, making this stock a risky investment. Their Buy rating should be approached with caution due to potential risks in financial, clinical, manufacturing, legal and intellectual property, regulatory, competition, commercial, pipeline, and dilution aspects.